Egalet and RedHill Biopharma enter into an exclusive license agreement
December 30, 2009
Amarin’s AMR101 for Huntington’s disease Marketing Authorization Application accepted for review by EMEA
April 8, 2009
Kamada Announces that it had Succesfully Met the Primary Endpoint in its US Phase III Clinical Trial with Intravenous AAT
April 2, 2008
Your Privacy |
Legal Notes |
info@proseedcapital.com